和譽-B盤中漲超4% 治療軟骨發育不全藥物臨牀申請獲CDE批准

新浪港股

03-26

熱點欄目自選股數據中心行情中心資金流向模擬交易

客戶端

　　和譽-B（02256）盤中漲超4%，截至發稿，股價上漲3.06%，現報8.09港元，成交額874.50萬港元。

　　和譽醫藥今早宣佈，其自主研發的高選擇性小分子FGFR2/3抑制劑ABSK061已獲中國國家藥品監督管理局藥品審評中心（CDE）批准治療兒童軟骨發育不全的臨牀研究許可。據悉，ABSK061是和譽醫藥獨立自主研發並擁有全球知識產權的一款新一代口服、高活性、高選擇性小分子FGFR2/3抑制劑，也是全球範圍內第一款進入臨牀的FGFR2/3選擇性抑制劑。

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：盧昱君

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2522657368"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522657368\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522657368?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-26 10:36","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2522657368","market":"sg","top_or_hot":-1,"title":"和譽-B盤中漲超4% 治療軟骨發育不全藥物臨牀申請獲CDE批准","media":"新浪港股","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/02256.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/02256\">和譽-B</a></span><span></span>（02256）盤中漲超4%，截至發稿，股價上漲3.06%，現報8.09港元，成交額874.50萬港元。</p>\n<p>　　和譽醫藥今早宣佈，其自主研發的高選擇性小分子FGFR2/3抑制劑ABSK061已獲中國國家藥品監督管理局藥品審評中心（CDE）批准治療兒童軟骨發育不全的臨牀研究許可。據悉，ABSK061是和譽醫藥獨立自主研發並擁有全球知識產權的一款新一代口服、高活性、高選擇性小分子FGFR2/3抑制劑，也是全球範圍內第一款進入臨牀的FGFR2/3選擇性抑制劑。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和譽-B盤中漲超4% 治療軟骨發育不全藥物臨牀申請獲CDE批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和譽-B盤中漲超4% 治療軟骨發育不全藥物臨牀申請獲CDE批准\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪港股</strong><span class=\"h-time small\">2025-03-26 10:36</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/02256.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/02256\">和譽-B</a></span><span></span>（02256）盤中漲超4%，截至發稿，股價上漲3.06%，現報8.09港元，成交額874.50萬港元。</p>\n<p>　　和譽醫藥今早宣佈，其自主研發的高選擇性小分子FGFR2/3抑制劑ABSK061已獲中國國家藥品監督管理局藥品審評中心（CDE）批准治療兒童軟骨發育不全的臨牀研究許可。據悉，ABSK061是和譽醫藥獨立自主研發並擁有全球知識產權的一款新一代口服、高活性、高選擇性小分子FGFR2/3抑制劑，也是全球範圍內第一款進入臨牀的FGFR2/3選擇性抑制劑。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-26/doc-ineqxyis5004425.shtml\">新浪港股</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-26/doc-ineqxyis5004425.shtml","article_id":"2522657368","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522657368","pubTimestamp":1742956560,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　和譽-B盤中漲超4%，截至發稿，股價上漲3.06%，現報8.09港元，成交額874.50萬港元。　　和譽醫藥今早宣佈，其自主研發的高選擇性小分子FGFR2/3抑制劑ABSK061已獲中國國家藥品監督管理局藥品審評中心批准治療兒童軟骨發育不全的臨牀研究許可。據悉，ABSK061是和譽醫藥獨立自主研發並擁有全球知識產權的一款新一代口服、高活性、高選擇性小分子FGFR2/3抑制劑，也是全球範圍內第一款進入臨牀的FGFR2/3選擇性抑制劑。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4017":"黄金","BK1161":"生物科技","02256":"和誉-B","CDE":"科尔黛伦矿业"},"translate_title":"Heyu-B rose more than 4% intraday, clinical application for drugs for treating achondroplasia was approved by CDE","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02256":1,"CDE":1},"content_text":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　和譽-B（02256）盤中漲超4%，截至發稿，股價上漲3.06%，現報8.09港元，成交額874.50萬港元。\n　　和譽醫藥今早宣佈，其自主研發的高選擇性小分子FGFR2/3抑制劑ABSK061已獲中國國家藥品監督管理局藥品審評中心（CDE）批准治療兒童軟骨發育不全的臨牀研究許可。據悉，ABSK061是和譽醫藥獨立自主研發並擁有全球知識產權的一款新一代口服、高活性、高選擇性小分子FGFR2/3抑制劑，也是全球範圍內第一款進入臨牀的FGFR2/3選擇性抑制劑。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}